Join Now

Project Details
  • Title: A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Adults with WHO Grade II Gliomas
  • Date Proposed: 06/07/2008
  • Amount Requested: $60,000.00
  • Amount we Paid: $60,000.00
  • Paid Date: 07/08/2008
  • Stauts: Funded - waiting to begin!
  • Research name: Hideho Okada, MD PhD
  • Hospital: University of Pittsburgh Cancer Institute
  • Grey Ribbon Crusade Participants:
    • Musella Foundation For Brain Tumor Research & Information, Inc
    • Oligo Fund of Musella Foundation
    • Unlocking Brain Tumors, Inc
  • Simple Description: World Health Organization [WHO] Grade II gliomas are slow-growing glioma with an intrinsic tendency to progress to aggressive malignant glioma. There are no standard radiation therapy regimens that can improve the survival and quality of life of these patients. We have been dedicated to the development of novel immunotherapy approaches for patients with gliomas. The goal is to improve the ability of the immune system to attack and destroy glioma cells. To this end, we have dedicated our major efforts to identify and characterize the key antigenic components (epitopes) in proteins that are commonly produced in glioma cells (glioma-associated antigens; GAAs), thereby allowing us to efficiently and safely direct the induction of cytotoxic T-lymphocytes (CTLs) against glioma cells. In the current proposal, we plan to test if GAA-specific peptide vaccines can induce CTL responses safely in participants with WHO grade II glioma. We believe these patients are particularly suitable for vaccine therapy because their immune system appears to be relatively well maintained in contrast to patients with malignant glioma, who routinely receive immuno-suppressive chemo-/radiotherapy. In addition, as vaccine treatments have relatively mild toxicity profiles based on previous trials, quality of life is expected to be well maintained in participating patients. Eligible participants will receive the first course of vaccinations every three weeks for eight times. Information from this pilot study will provide valuable information as to whether GAA-specific T-cell response can be safely induced and biological understanding as to how tumor cells can escape from the immune surveillance. This study will also provide a basis for the design of subsequent trials in larger number of patients through nation wide brain tumor therapy consortiums.
  • Interim report: Proceeding nicely
  • Final Report: Project is completed and will be submitted for publication soon